Hostname: page-component-cd9895bd7-jkksz Total loading time: 0 Render date: 2024-12-20T22:46:41.990Z Has data issue: false hasContentIssue false

Frontiers in antimicrobial stewardship: antimicrobial use during end-of-life care

Published online by Cambridge University Press:  02 October 2023

Seohyuk Lee
Affiliation:
Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA
Rupak Datta*
Affiliation:
Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA Veterans Affairs Connecticut Healthcare System, West Haven, CT, USA
*
Corresponding author: Rupak Datta; Email: rupak.datta@yale.edu

Abstract

Type
Commentary
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
Copyright
© The Author(s), 2023. Published by Cambridge University Press on behalf of The Society for Healthcare Epidemiology of America

Improving the use of antimicrobials across healthcare settings is a national priority. While considerable literature has accumulated regarding antimicrobial stewardship across the continuum of care, new frontiers for implementation remain. 1 Antimicrobial stewardship during end-of-life care is unique because its principles are employed in the context of palliative care. Understanding how antimicrobials facilitate palliative care – with its focus on management of symptoms, psychosocial support, and assistance with decision-making – offers new opportunities to optimize the reach and effectiveness of antimicrobial stewardship. Reference Rome, Luminais, Bourgeois and Blais2 Nevertheless, many aspects of this area warrant increased scrutiny by stakeholders.

End-of-life care

There is no standardized definition of end-of-life. Reference Bennett, Davies and Higginson3 In general, end-of-life refers to the final days to weeks of a life-limiting illness. However, alternative definitions encompass the entire time interval of a life-limiting illness, such as advanced cancer or advanced dementia, when death would not be unexpected. 4 Palliative care can complement curative therapies during the end-of-life period and may be delivered by diverse clinicians (eg, physicians and advanced practice providers) and healthcare settings (eg, acute care, long-term care, and home-based care). Reference Buss, Rock and McCarthy5 Such heterogeneity in the provision of end-of-life care can complicate the implementation of effective antimicrobial stewardship.

Estimates of antimicrobial use

Patients near the end-of-life are prone to infection due to the prevalence of immunosuppression, multimorbidity, cognitive impairment, and device utilization. Reference Groeger, Lucas and Thaler6Reference Mitchell, Teno and Kiely9 Consequently, exposure to antimicrobials is common during palliative care. Among hospitalized patients experiencing cancer-related death, 87% received antimicrobials during hospitalization, and over one-third of these patients received antimicrobial therapy following transition to comfort care. Reference Thompson, Silveira, Vitale and Malani10,Reference Oh, Kim and Kim11 Among nursing home residents with advanced dementia, more than 40% received antimicrobials in the 2 weeks prior to death. Reference D’Agata and Mitchell12 Nationally, 27% of hospice patients received ≥ 1 antimicrobial during the last week of life, and over 1 in 5 patients discharged to hospice were continued on antimicrobials. Reference Albrecht, McGregor, Fromme, Bearden and Furuno13,Reference Furuno, Noble and Horne14 In one recent meta-analysis, based on data from 72 studies in which the definition of end-of-life ranged from the day of death to 6 months prior to death, over 50% of patients near the end-of-life receive antimicrobials across healthcare settings. Reference Marra, Puig-Asensio, Balkenende, Livorsi, Goto and Perencevich15 Importantly, evidence to support the presence of bacterial infection was insufficient in most studies, suggesting that many antimicrobial prescriptions are potentially inappropriate. Reference Clark, Halford, Herndon and Middendorf16,Reference Mitchell, Shaffer and Loeb17 These data indicate that exposure to antimicrobial therapy is substantial during end-of-life care and establish ripe targets for future research and quality improvement.

Aligning antimicrobial therapy with goals of care

Goals of care often vary from survival to comfort near the end-of-life. Yet, to date, no study has rigorously evaluated the impact of antimicrobial therapy on mortality or relief of symptoms in an end-of-life population. Two systematic reviews provided limited data to support the use of antimicrobial therapy to achieve relief of symptoms among patients receiving palliative care. Reference Marra, Puig-Asensio, Balkenende, Livorsi, Goto and Perencevich15,Reference Rosenberg, Albrecht and Fromme18 It remains unknown what specific symptoms associated with infection are most likely to benefit from antimicrobial therapy during this period. Limited evidence suggests that genitourinary symptoms related to urinary tract infection may improve with antimicrobial therapy, whereas those associated with oral cavity, skin and soft tissue, and bloodstream infections may be less responsive. Reference Reinbolt, Shenk, White and Navari19,Reference Clayton, Fardell, Hutton-Potts, Webb and Chye20 With respect to respiratory symptoms, there are conflicting data. In one American study of patients with advanced dementia and suspected pneumonia, antimicrobial therapy was associated with decreased comfort but improved survival. Reference Givens, Jones, Shaffer, Kiely and Mitchell21 In contrast, in two Dutch studies, antimicrobial therapy was associated with lower symptomatic burden among patients with dementia who developed pneumonia. Reference van der Steen, Ooms, van der Wal and Ribbe22,Reference Van Der Steen, Pasman, Ribbe, Van Der Wal and Onwuteaka-Philipsen23 These data suggest that the use of antimicrobial therapy for the symptomatic management of infection may lack benefit in long-term care and hospice settings. In acute care settings, withholding antimicrobials should be considered when survival is not a primary goal given the high potential for harm and limited data on efficacy related to relief of symptoms. Reference Barlam, Cosgrove and Abbo24 Ultimately, antimicrobial therapy should be deemed aggressive care during the end-of-life period and be administered orally whenever possible based on good practice recommendations. Reference Barlam, Cosgrove and Abbo24

Behavioral and decision-making aspects

It is likely that behavioral and decision-making aspects are key barriers to the implementation of antimicrobial stewardship during end-of-life care. Despite the substantial harms associated with antimicrobial therapy, such as adverse drug events, Clostridioides difficile infection, and antimicrobial resistance, the pressures to prescribe are powerful and often multifactorial. For example, among 283 surveyed physicians affiliated with an academic medical center, 86% and 75% continued antimicrobial therapy during end-of-life care to honor the request of patients and family members, respectively. Reference Gaw, Hamilton, Gerber and Szymczak25 These providers often cited a desire to avoid the perception that they were giving up on the patient. Reference Gaw, Hamilton, Gerber and Szymczak25 Among patients discharged to hospice, nearly 20% of prescriptions were linked to the specific desire of patients and/or their family members to receive antimicrobial treatment. Reference Servid, Noble, Fromme and Furuno26 Additionally, the decision to withhold or withdraw antimicrobial therapy may be sensitive to social dynamics within interdisciplinary care teams, including hierarchy, professional power, and shared accountability. Reference Stiel, Krumm and Pestinger27Reference Charani, Castro-Sanchez and Sevdalis29 These factors, along with many others (eg, fear of negative patient satisfaction scores, perceived burden of treatment, institutional culture, and ethical aspects of end-of-life care) lie in the backdrop of prognostic uncertainty. Reference Gaw, Hamilton, Gerber and Szymczak25,Reference Broom, Kirby, Gibson, Post and Broom30,Reference Teixeira Rodrigues, Roque, Falcão, Figueiras and Herdeiro31 Given that predicting death is inevitably imprecise, physicians may favor continuing antimicrobials among patients receiving end-of-life care.

Future directions

There are many potential pathways to promote antimicrobial stewardship during end-of-life care. Good practice recommendations emphasize shared decision-making about future care and agreement regarding goals of treatment as part of advance care planning. Reference Seaton, Cooper and Fairweather32 These recommendations, combined with recent survey data, underscore a role for educational programs (eg, training modules and communication simulation exercises) to increase the integration of antimicrobial use into advance care planning at the time of enrollment in long-term care or hospice programs. Reference Datta, Topal and McManus33,Reference Datta, Topal, McManus, Dembry, Quagliarello and Juthani-Mehta34 At the facility level, multifaceted interventions supported by information technology including antimicrobial restrictions, clinical decision support tools, and/or comfort care order sets may be designed and evaluated specifically for patients receiving end-of-life care in acute care settings. The benefits and harms of antimicrobial use during end-of-life care using valid and reliable metrics involving patient and caregiver relevant outcomes also require investigation across racially and ethnically diverse populations. Additionally, there is a need to integrate best practices related to antimicrobial stewardship, such as the “Four Moments of Antibiotic Decision Making,” into palliative care settings; this may be achieved using methods of implementation science. 35,Reference Livorsi, Drainoni and Reisinger36 Finally, there are no national or international guidelines to facilitate decision-making related to antimicrobial use during end-of-life care. Future studies may consider addressing this gap in knowledge using methods that combine expert opinion and evidence in a systematic manner. Reference Hohmann, Brand, Rossi and Lubowitz37

In conclusion, antimicrobial use is prevalent during end-of-life care. As antimicrobial stewardship programs strive to optimize antimicrobial prescribing across the continuum of care, end-of-life care represents a challenging new frontier for antimicrobial stewards to improve clinical outcomes and reduce antimicrobial-associated harms.

Acknowledgments

This work was supported with resources from and the use of facilities at the Hospital Epidemiology and Infection Prevention Program at the Veterans Affairs Connecticut Healthcare System, West Haven, Connecticut.

Financial support

Dr Datta was supported by a career development award from the National Institute of Aging (NIA) of the National Institutes of Health (NIH) under Award Number U54AG063546, which funds the NIA Imbedded Pragmatic Alzheimer’s Disease and AD-Related Dementias Clinical Trials Collaboratory (NIA IMPACT Collaboratory). This publication was made possible by CTSA Grant Award UL1 TR001863 from the National Center for Advancing Translational Science (NCATS), a component of the NIH, the Operations Core of the Claude D. Pepper Older Americans Independence Center at Yale School of Medicine (P30AG021342), the Yale Physician-Scientist Development Award, and the Society for Healthcare Epidemiology of America Epidemiology Competition Award. The funders had no role in the writing of this report or in the decision to submit the paper for publication.

Competing interests

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Veterans Affairs. All authors report no conflicts of interest relevant to this article.

References

Antibiotic Use in the United States. 2022 Update: Progress and Opportunities. Centers for Disease Control and Prevention. https://www.cdc.gov/antibiotic-use/stewardship-report/current.html. Published 2022. Accessed February 2, 2023.Google Scholar
Rome, RB, Luminais, HH, Bourgeois, DA, Blais, CM. The role of palliative care at the end of life. Ochsner J 2011;11:348352.Google ScholarPubMed
Bennett, MI, Davies, EA, Higginson, IJ. Delivering research in end-of-life care: problems, pitfalls and future priorities. Palliat Med 2010;24:456461.CrossRefGoogle ScholarPubMed
Australian Commission on Safety and Quality in Health Care. National consensus statement: essential elements for safe and high-quality end-of-life care. https://www.safetyandquality.gov.au/publications-and-resources/resource-library/national-consensus-statement-essential-elements-safe-and-high-quality-end-life-care. Published 2015. Accessed February 2, 2023.Google Scholar
Buss, MK, Rock, LK, McCarthy, EP. Understanding palliative care and hospice: a review for primary care providers. Mayo Clin Proc 2017;92:280286.CrossRefGoogle ScholarPubMed
Groeger, JS, Lucas, AB, Thaler, HT, et al. Infectious morbidity associated with long-term use of venous access devices in patients with cancer. Ann Intern Med 1993;119:11681174.CrossRefGoogle ScholarPubMed
Rolston, KV. Infections in cancer patients with solid tumors: a review. Infect Dis Ther 2017;6:6983.CrossRefGoogle ScholarPubMed
Homsi, J, Walsh, D, Panta, R, Lagman, R, Nelson, KA, Longworth, DL. Infectious complications of advanced cancer. Support Care Cancer 2000;8:487492.Google ScholarPubMed
Mitchell, SL, Teno, JM, Kiely, DK, et al. The clinical course of advanced dementia. N Engl J Med 2009;361:15291538.CrossRefGoogle ScholarPubMed
Thompson, AJ, Silveira, MJ, Vitale, CA, Malani, PN. Antimicrobial use at the end of life among hospitalized patients with advanced cancer. Am J Hosp Palliat Care 2012;29:599603.CrossRefGoogle ScholarPubMed
Oh, DY, Kim, JH, Kim, DW, et al. Antibiotic use during the last days of life in cancer patients. Eur J Cancer Care 2006;15:7479.CrossRefGoogle ScholarPubMed
D’Agata, E, Mitchell, SL. Patterns of antimicrobial use among nursing home residents with advanced dementia. Arch Intern Med 2008;168:357362.CrossRefGoogle ScholarPubMed
Albrecht, JS, McGregor, JC, Fromme, EK, Bearden, DT, Furuno, JP. A nationwide analysis of antibiotic use in hospice care in the final week of life. J Pain Symptom Manage 2013;46:483490.CrossRefGoogle ScholarPubMed
Furuno, JP, Noble, BN, Horne, KN, et al. Frequency of outpatient antibiotic prescription on discharge to hospice care. Antimicrob Agents Chemother 2014;58:54735477.CrossRefGoogle ScholarPubMed
Marra, AR, Puig-Asensio, M, Balkenende, E, Livorsi, DJ, Goto, M, Perencevich, EN. Antibiotic use during end-of-life care: a systematic literature review and meta-analysis. Infect Control Hosp Epidemiol 2021;42:523529.CrossRefGoogle ScholarPubMed
Clark, MD, Halford, Z, Herndon, C, Middendorf, E. Evaluation of antibiotic initiation tools in end-of-life care. Am J Hosp Palliat Care 2022;39:274281.CrossRefGoogle ScholarPubMed
Mitchell, SL, Shaffer, ML, Loeb, MB, et al. Infection management and multidrug-resistant organisms in nursing home residents with advanced dementia. JAMA Intern Med 2014;174:16601667.CrossRefGoogle ScholarPubMed
Rosenberg, JH, Albrecht, JS, Fromme, EK, et al. Antimicrobial use for symptom management in patients receiving hospice and palliative care: a systematic review. J Palliat Med 2013;16:15681574.CrossRefGoogle ScholarPubMed
Reinbolt, RE, Shenk, AM, White, PH, Navari, RM. Symptomatic treatment of infections in patients with advanced cancer receiving hospice care. J Pain Symptom Manage 2005;30:175182.CrossRefGoogle ScholarPubMed
Clayton, J, Fardell, B, Hutton-Potts, J, Webb, D, Chye, R. Parenteral antibiotics in a palliative care unit: prospective analysis of current practice. Palliat Med 2003;17:4448.CrossRefGoogle Scholar
Givens, JL, Jones, RN, Shaffer, ML, Kiely, DK, Mitchell, SL. Survival and comfort after treatment of pneumonia in advanced dementia. Arch Intern Med 2010;170:11021107.CrossRefGoogle ScholarPubMed
van der Steen, JT, Ooms, ME, van der Wal, G, Ribbe, MW. Pneumonia: the demented patient’s best friend? Discomfort after starting or withholding antibiotic treatment. J Am Geriatr Soc 2002;50:16811688.CrossRefGoogle ScholarPubMed
Van Der Steen, JT, Pasman, HR, Ribbe, MW, Van Der Wal, G, Onwuteaka-Philipsen, BD. Discomfort in dementia patients dying from pneumonia and its relief by antibiotics. Scand J Infect Dis 2009;41:143151.CrossRefGoogle ScholarPubMed
Barlam, TF, Cosgrove, SE, Abbo, LM, et al. Implementing an antibiotic stewardship program: guidelines by the infectious diseases society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 2016;62:e51e77.CrossRefGoogle Scholar
Gaw, CE, Hamilton, KW, Gerber, JS, Szymczak, JE. Physician perceptions regarding antimicrobial use in end-of-life care. Infect Control Hosp Epidemiol 2018;39:383390.CrossRefGoogle ScholarPubMed
Servid, SA, Noble, BN, Fromme, EK, Furuno, JP. Clinical intentions of antibiotics prescribed upon discharge to hospice care. J Am Geriatr Soc 2018;66:565569.CrossRefGoogle ScholarPubMed
Stiel, S, Krumm, N, Pestinger, M, et al. Antibiotics in palliative medicine—results from a prospective epidemiological investigation from the HOPE survey. Support Care Cancer 2012;20:325333.CrossRefGoogle ScholarPubMed
Papoutsi, C, Mattick, K, Pearson, M, Brennan, N, Briscoe, S, Wong, G. Social and professional influences on antimicrobial prescribing for doctors-in-training: a realist review. J Antimicrob Chemother 2017;72:24182430.CrossRefGoogle ScholarPubMed
Charani, E, Castro-Sanchez, E, Sevdalis, N, et al. Understanding the determinants of antimicrobial prescribing within hospitals: the role of “prescribing etiquette.” Clin Infect Dis 2013;57:188196.CrossRefGoogle ScholarPubMed
Broom, A, Kirby, E, Gibson, AF, Post, JJ, Broom, J. Myth, manners, and medical ritual: defensive medicine and the fetish of antibiotics. Qual Health Res 2017;27:19942005.CrossRefGoogle ScholarPubMed
Teixeira Rodrigues, A, Roque, F, Falcão, A, Figueiras, A, Herdeiro, MT. Understanding physician antibiotic prescribing behaviour: a systematic review of qualitative studies. Int J Antimicrob Agents 2013;41:203212.CrossRefGoogle ScholarPubMed
Seaton, RA, Cooper, L, Fairweather, J, et al. Antibiotic use towards the end of life: development of good practice recommendations. [published online ahead of print January 19, 2021]. BMJ Support Palliat Care doi: 10.1136/bmjspcare-2020-002732.CrossRefGoogle Scholar
Datta, R, Topal, J, McManus, D, et al. Education needed to improve antimicrobial use during end-of-life care of older adults with advanced cancer: a cross-sectional survey. Palliat Med 2021;35:236241.CrossRefGoogle ScholarPubMed
Datta, R, Topal, J, McManus, D, Dembry, LM, Quagliarello, V, Juthani-Mehta, M. Perspectives on antimicrobial use at the end of life among antibiotic stewardship programs: a survey of the Society for Healthcare Epidemiology of America Research Network. Infect Control Hosp Epidemiol 2019;40:10741076.CrossRefGoogle Scholar
Four Moments of Antibiotic Decision Making. Agency for Healthcare Research and Quality, Rockville, MD. https://www.ahrq.gov/antibiotic-use/acute-care/four-moments/index.html. Published 2019. Accessed February 2, 2023.Google Scholar
Livorsi, DJ, Drainoni, ML, Reisinger, HS, et al. Leveraging implementation science to advance antibiotic stewardship practice and research. Infect Control Hosp Epidemiol 2022;43:139146.CrossRefGoogle ScholarPubMed
Hohmann, E, Brand, JC, Rossi, MJ, Lubowitz, JH. Expert opinion is necessary: Delphi panel methodology facilitates a scientific approach to consensus. Arthroscopy 2018;34:349351.CrossRefGoogle Scholar